Fighting Breast and Ovarian Cancer With a Lupus Antibody
After discovering a specific lupus antibody that can penetrate cancer cells and, with a grant from Women's Health Research at Yale, showing it makes cancer cells vulnerable to standard treatments, Dr. Peter Glazer and his colleagues are moving a treatment to clinical trials.
Digestive Diseases Program Facilitates Research for Investigators and Study Coordinators
Investigators in the Yale School of Medicine Section of Digestive Diseases are conducting clinical trials in a variety of areas, including fatty liver disease, hepatitis, inflammatory bowel disease, and primary sclerosing cholangitis. The studies serve to help patients with complicated conditions who either have no treatment options or who would like to try novel therapies.
Researchers Are Testing Paxlovid as a Treatment for Long COVID
Long COVID currently affects millions of people in the U.S. Symptoms can include brain fog, tremors, sleep disorders, and shortness of breath. The National Institutes of Health (NIH) and other academic medical centers recently launched clinical trials aimed at finding treatments for long COVID. Researchers think that there may be different causes of long COVID symptoms in different people, which is why they are conducting different clinical trials in many centers around the country.Source: Verywell Health
Joining medical clinical trials and receiving new treatments can be tough. Here’s how a CT hospital is changing that.
Patients with difficult-to-treat diseases can join clinical trials, the vital studies that test new medications, more easily now, according to Dr. Roy Herbst, deputy director of the Yale Cancer Center.Source: Hartford Courant
Tagrisso demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
Positive high-level results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.Source: AstraZeneca
Confronting Health Disparities in Clinical Trials
Boehringer Ingelheim is partnering with Yale Cancer Center and Patricia M. LoRusso, DO, PhD, FASCO, to improve access to early-phase clinical cancer trials by reducing health disparities such as lack of transportation, childcare and financial or food insecurity.Source: Boehringer Ingelheim